Core Insights - The company, Zhiyun Health, reported a revenue of 893 million RMB and a gross profit of 331 million RMB for the six months ending June 30, 2025, with R&D expenses amounting to 26.375 million RMB [1] Group 1: Hospital SaaS Performance - The company has installed chronic disease management SaaS in 2,774 hospitals, capturing 40% of the top 100 hospitals and over 20% penetration in tertiary hospitals [1] - The hospital SaaS automates and standardizes electronic health records, prescriptions, test results, and other medical data, enhancing diagnostic procedures, treatment efficiency, and reducing medical errors [1] Group 2: Pharmacy SaaS Performance - The company has installed pharmacy SaaS in 269,360 pharmacies, representing approximately 40% of the total pharmacies in China [1] - Over the years, the company has issued more than 1 billion prescriptions through its internet hospital, allowing patients, especially those with chronic diseases, to receive online diagnoses and prescriptions at pharmacies [1] Group 3: Financial Transformation - In the first half of the year, the company achieved a net cash inflow from operating activities of 28.7 million RMB, a significant improvement from a cash outflow of 196 million RMB in the same period of 2024 [2] - The company is focusing on a P2M strategy for short-term transformation to achieve stable cash flow and profitability, while long-term goals include monetizing data assets and creating a closed-loop management system for chronic diseases through medical data sharing [2]

Core Insights - Zhiyun Health (09955) reported a 20.3% year-on-year increase in revenue to 890 million yuan for the first half of the year [1] - Adjusted gross margin improved by 29.3 percentage points to 49.9%, while net loss narrowed by 23.3% [1] - Operating cash flow turned positive for the first time in history, with a net inflow of 28.65 million yuan compared to a net outflow of 195 million yuan in the same period last year [1] Revenue Breakdown - P2M solution revenue reached 260 million yuan, marking a significant year-on-year growth of 142.1% [1] - The company has launched six core products and has eight new products in the pipeline [1] Technological Advancements - The AI dual model (ClouD GPT/DTx) has completed the data-monetization loop, and the gestational diabetes solution has been published in an international journal [1] Market Presence - The company's SaaS has covered over 2,700 hospitals and nearly 270,000 pharmacies [1] - Management indicated plans to accelerate the commercialization of P2M solutions to solidify its position as a leader in chronic disease digitalization [1]

Core Viewpoint - The AI healthcare sector is gaining significant market attention, surpassing the previously popular innovative drug sector, driven by institutional fund reallocations towards AI medical stocks as they show potential for growth and recovery [1][2]. Financial Performance - Zhiyun Health reported a substantial improvement in profitability in its mid-2025 financial report, with a revenue of 889 million yuan, reflecting a year-on-year increase of 20.3% when adjusted for comparable periods [5][6]. - The adjusted gross margin reached 49.9%, up 4.2 percentage points year-on-year, indicating a significant enhancement in the company's core business profitability [5][6]. - The company achieved its first positive operating cash flow of 28.65 million yuan, marking a shift towards a positive operational cycle [8]. Strategic Transformation - Zhiyun Health's strategic shift towards AI-enabled high-value sectors is showing results, with a focus on subscription solutions and P2M (Patient to Industry) solutions, which now account for 77.5% of gross profit [6][9]. - The company has successfully implemented a dual-architecture strategy centered on "AI SaaS + P2M," enhancing operational efficiency across various healthcare scenarios [9][12]. Market Position and Growth Potential - The company has established a strong presence in both hospital and pharmacy sectors, with its SaaS solutions covering 2,774 hospitals and nearly 27,000 pharmacies, translating to significant service volume and market leadership [12][13]. - The P2M solution revenue reached 260 million yuan, a year-on-year increase of 142.1%, driven by the growth of proprietary products and strategic partnerships with pharmaceutical companies [13][25]. Industry Trends and Policy Support - The AI healthcare sector is experiencing a favorable policy environment, with recent government initiatives promoting the integration of AI in healthcare, which aligns with Zhiyun Health's strategic focus [21][22]. - The demand for AI in clinical settings is increasing, with nearly half of doctors in primary and secondary hospitals having used AI clinical decision support systems, indicating a shift towards AI as a necessary tool in healthcare [23][25]. Long-term Vision - Zhiyun Health aims to leverage its accumulated healthcare data for monetization, creating a comprehensive ecosystem that connects all stakeholders in the healthcare process, thus enhancing its long-term growth potential [25][26].

Group 1 - The company reported a revenue of 893 million RMB and a gross profit of 331 million RMB for the six months ending June 30, 2025 [1] - Research and development expenses amounted to 26.375 million RMB [1] - The company has installed chronic disease management SaaS in 2,774 hospitals, covering 40% of the top 100 hospitals and over 20% penetration in tertiary hospitals [1] Group 2 - The company has installed pharmacy SaaS in 269,360 pharmacies, representing approximately 40% of the total pharmacies in China [1] - The company has issued over 1 billion prescriptions through its internet hospital [1] - The pharmacy SaaS allows customers, especially chronic disease patients, to access online diagnosis and prescriptions upon entering the pharmacy [1] Group 3 - The company achieved a net cash inflow from operating activities of 28.7 million RMB in the first half of the year, compared to a net cash outflow of 196 million RMB in the same period of 2024 [2] - The short-term transformation strategy focuses on P2M to achieve stable cash flow and profitability [2] - The long-term goal of the transformation is to monetize data assets and connect hospitals, pharmacies, pharmaceutical companies, patients, and payers through medical data sharing [2]

（於開曼群島註冊成立的有限公司） （股份代號：9955） 提名委員會之職權範圍 3.12 委員會會議的完整記錄應由秘書或公司秘書（如不時適用）保管，並 應於任何董事發出合理通知時於任何合理時間內供公開查閱。 3.13 秘書須編製委員會會議記錄及該等會議的個人出席記錄，並於任何 委員會會議結束後合理時間內寄發予董事會全體成員，以供彼等提 出意見及記錄。僅就記錄出席情況而言，委員會候補成員的出席記錄 將不會計為委員會相關成員本身的出席記錄。會議記錄應充分詳細 地記錄已審議的事宜及所達成的決定，包括董事提出的任何疑慮或 表達的反對意見。 3.14 在不影響上市規則任何規定的情況下，全體委員會成員（或其各自的 候補成員）簽署的書面決議案應屬正確及有效，猶如該決議案已在正 式召開及舉行的委員會會議上獲通過。 智雲健康科技集團（「* 本公司」）根據本公司董事會（「董事會」）於2022年5月29日 通過的一項決議案成立提名委員會（「委員會」）。下文所載為委員會的職權範 圍（「職權範圍」）。職權範圍可供以中英文版本閱覽。職權範圍的中英版本如有 任何歧義，概以英文版本為準。 – 1 – 1. 目的 1.1 委員會旨在物色、考慮 ...

智雲健康科技集團*（「本公司」）董事（「董事」）會（「董事會」）成員如下。 執行董事 匡明先生 （董事長兼行政總裁） 左穎暉女士 獨立非執行董事 洪偉力博士 張賽音先生 Ang Khai Meng先生 （於開曼群島註冊成立的有限公司） （股份代號：9955） 董事名單與其角色和職能 董事會轄下設有三個董事會委員會。下表提供了各董事任職的委員會成員資料。 | 董事會委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | | 董事 | | | | | 匡明先生 | | 成員 | 主席 | | 左穎暉女士 | | | 成員 | | 洪偉力博士 | 成員 | 主席 | 成員 | | 張賽音先生 | 主席 | 成員 | 成員 | | Ang Khai Meng先生 | 成員 | | 成員 | 2025年8月27日 * 僅供識別 ...

（於開曼群島註冊成立的有限公司） （股份代號：9955） (1) 截至2025年6月30日止六個月中期業績公告； (2) 終止須予披露交易； (3) 須予披露交易；及 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 (4) 提名委員會組成變動 本公司董事欣然宣佈本集團報告期內的未經審核綜合中期業績，連同2024年同 期的比較數字。該等中期業績已經本公司審核委員會審閱。 於本公告內，「我們」及「我們的」指本公司，倘文義另有所指，則指本集團。本 公告所載若干金額及百分比數字經過約整，或者四捨五入至小數點後一位或 兩位。任何表格、圖表或其他地方列出的總數及金額總和之間的任何差異均由 約整造成。 – 1 – 財務摘要 | | 截至6月30日止六個月 | | | | --- | --- | --- | --- | | | 2025年 | 2024年 | 變動(%) | | | 人民幣千元 | 人民幣千元 | | | | （未經審核）（未經審核） | | | | ...

Core Insights - The core concept of the article revolves around the rapid development and significant market growth of the full-course management model in healthcare, which emphasizes a patient-centered approach and integrates various stages of care from prevention to rehabilitation [1][16]. Group 1: Overview of Full-Course Management - Full-course management is a disease care model that focuses on individual patients, adhering to medical guidelines and clinical consensus, and involves multidisciplinary collaboration [2][4]. - This model encompasses integrated services for disease prevention, treatment, rehabilitation, and care, covering follow-up, medication management, and home rehabilitation [2][4]. Group 2: Market Growth and Trends - The market size for full-course management in China is projected to reach 61.4 billion yuan in 2024, reflecting a year-on-year growth of 45.2% [1][16]. - The overall healthcare management service market in China is expected to grow from 10.6 trillion yuan in 2020 to 15.9 trillion yuan in 2024, with a compound annual growth rate of 10.6% [14]. Group 3: Industry Landscape - The full-course management industry in China is characterized by a fragmented market with over a hundred participants, but most have limited business scale and operate in specific geographic areas or medical specialties [18]. - The market share of the top five companies in the full-course management sector is only 6.3% as of 2024, indicating a lack of dominant players [18]. Group 4: Future Opportunities - By 2030, the market size for full-course management is expected to exceed 360 billion yuan, with a compound annual growth rate of 34.6% from 2024 to 2030 [20]. - The increasing health awareness among the Chinese population is driving demand for full-cycle health services, creating significant opportunities for companies in the full-course management sector [20][10]. Group 5: Technological and Structural Developments - AI technology is anticipated to play a crucial role in enhancing the full-course management industry by addressing physician capacity constraints and improving healthcare quality and efficiency [23]. - The industry is expected to see an increase in concentration as competitive pressures rise, allowing technically proficient and market-advantaged companies to gain larger market shares [25].

Group 1 - The stock price of Zhiyun Health (9955.HK) rose by 10.53% to HKD 1.68, reaching a nearly six-month high since February 25, with a market capitalization exceeding HKD 1 billion [1] - The stock has increased over 84% since hitting a year-to-date low of HKD 0.91 on April 9, indicating strong recovery and investor interest [1] - Zhiyun Health's AI model achieved a breakthrough in treating gestational diabetes (GDM), led by Dr. Liu Hongying, and the research was published in the prestigious journal JMIR, showcasing the company's advancements in endocrine and women's health [1] Group 2 - Analysts from Galaxy Securities recommend focusing on the AI sector, particularly on companies with strong foundational technology, leading international presence, and monetization capabilities in AI applications, highlighting the potential of AI in healthcare [1] - Founder Securities noted that the "AI+" approach is driving revolutionary developments in the medical industry, with rapid advancements in high-end innovative equipment such as brain-computer interfaces and surgical robots, as domestic companies accelerate self-research and collaborative efforts [1]

消息面上，智云健康AI大模型取得新突破。7月底有消息称，由智云健康首席医学官刘红樱博士带领的医学团队，借助公司自主研发的医疗大模型Cloud DTx，成功解锁了妊娠糖尿病(GDM)治疗的新方案，该研究已被国际顶级医学信息期刊JMIR收录，标志着智云健康在内分泌和女性健康领域的科研能力实 现了进一步飞跃。 银河证券研报认为，建议仍聚焦人工智能主赛道，重点把握硬核底座、出海龙头、场景货币化能力预期兑现的AI+应用龙头公司等三条主线，关注AI+医疗 龙头。方正证券亦指，"人工智能+"驱动医疗产业革命性发展，脑机接口、手术机器人等高端创新设备加速落地和应用拓展，国产企业加速自研与合作布 局，AI医疗进入百花盛开时刻。(格隆汇) 智云健康(9955.HK)今日盘中一度涨10.53%至1.68港元，股价创2月25日以来近半年新高，市值重回10亿港元上方。该股今年4月9日盘中曾触及年内低点0.91 港元，迄今逾4个月的时间，股价已累涨超84%。 ...